4102.Two

The company's capital structure is characterized by a market price of 17.15 TWD per share and a market capitalization of 726.71 million TWD. The price-to-book ratio is 1.24, indicating that the market value is slightly above the book value of the company's equity. The company's liquidity position is assessed as medium, with a current ratio of 1.92, suggesting it has sufficient current assets to cover its current liabilities. However, the company has a negative net cash position after subtracting total debt, which is a key liquidity flag.

Profitability metrics show that the company is currently unprofitable, with a net loss of 14.36 million TWD and an operating loss of 19.83 million TWD. The return on equity is -2.44%, and the return on assets is -1.55%, both indicating poor performance relative to the capital invested. The gross profit margin is 19.94%, which is below the industry median for pharmaceutical companies, suggesting that the company is not efficiently converting revenue into profit.

The company's revenue is concentrated in a few key markets, with the majority of its sales coming from its core therapeutic areas. The company does not disclose specific geographic revenue breakdowns, but its operations are primarily focused in Taiwan. This concentration may expose the company to regional economic and regulatory risks.

The company's growth trajectory is uncertain, with no specific revenue growth targets provided in the latest financial reports. The company's operating cash flow is negative, and its free cash flow is -67.44 million TWD, indicating that it is not generating sufficient cash from operations to fund its capital expenditures. The company's capital expenditures for the period were 42.13 million TWD, which is a significant outlay for a company with negative operating cash flow.

The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The company has a debt-to-equity ratio of 0.27, which is relatively low, but the negative net cash position is a concern. The company has not issued additional shares recently, and there is no indication of near-term dilution pressure. The company's risk profile is further complicated by its negative operating and net income, which may affect its ability to service debt and maintain operations.

Recent events and filings do not indicate any significant changes in the company's business strategy or financial position. The company's latest financial report, filed in accordance with local regulations, does not mention any material events that would significantly impact its operations or financial health. The company's management has not provided any forward-looking statements that suggest a change in the current trajectory.